LoginSignup
Beigene ADS Representing logo

Beigene ADS Representing

Stock
Stock
ISIN: US07725L1026
Ticker: BGNE
US07725L1026
BGNE

Price

Price

Frequently asked questions

What is Beigene ADS Representing's market capitalization?

The market capitalization of Beigene ADS Representing is $21.70B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Beigene ADS Representing?

Beigene ADS Representing's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.666. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Beigene ADS Representing's stock?

Currently, 9 analysts cover Beigene ADS Representing's stock, with a consensus target price of $25.66. Analyst ratings provide insights into the stock's expected performance.

What is Beigene ADS Representing's revenue over the trailing twelve months?

Over the trailing twelve months, Beigene ADS Representing reported a revenue of $3.27B.

What is the EBITDA for Beigene ADS Representing?

Beigene ADS Representing's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$896.28M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Beigene ADS Representing?

Beigene ADS Representing has a free cash flow of -$1.15B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

How many employees does Beigene ADS Representing have, and what sector and industry does it belong to?

Beigene ADS Representing employs approximately 10,473 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Beigene ADS Representing's shares?

The free float of Beigene ADS Representing is 1.31B. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $21.70B

EPS (TTM)

 -$0.666

Free Float

 1.31B

Revenue (TTM)

 $3.27B

EBITDA (TTM)

 -$896.28M

Free Cashflow (TTM)

 -$1.15B

Pricing

1D span
$190.87$197.76
52W span
$138.74$241.80

Analyst Ratings

The price target is $25.66 and the stock is covered by 9 analysts.

Buy

9

Hold

0

Sell

0

Information

BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.

10,473

Biotechnology & Drugs

Health Care

Identifier

ISIN

US07725L1026

Primary Ticker

BGNE

Knockouts

Join the conversation
Sign upLogin